Premium
Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network‐RIKEN (PGRN‐RIKEN) Collaboration
Author(s) -
Yee SW,
Momozawa Y,
Kamatani Y,
Tyndale RF,
Weinshilboum RM,
Ratain MJ,
Giacomini KM,
Kubo M
Publication year - 2016
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.405
Subject(s) - pharmacogenomics , genome wide association study , phenotype , disease , genetic association , biology , medicine , computational biology , genetics , bioinformatics , single nucleotide polymorphism , genotype , gene
Genomewide association studies (GWAS) have resulted in the identification of many heritable genetic factors that underlie risk for human disease or variation in physiologic traits. In contrast, there are fewer GWAS of drug response phenotypes, despite extensive unexplained interindividual variability. To address this urgent need, the NIH Pharmacogenomics Research Network (PGRN) and the Center for Integrative Medical Sciences (IMS) at RIKEN support a collaboration, PGRN‐RIKEN, with the goal of accelerating GWAS of drug response phenotypes.